Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs

Journal of Gastroenterology

Volumn 45, Issue 11, 2010, Pages 1097-1102

  Okumura, Toshikatsu ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Digestive organs; Thiazolidinedione (TZD) Anti cancer action

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CLAUDIN 4; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GELATINASE A; GELATINASE B; GLITAZONE DERIVATIVE; MITOCHONDRIAL DNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME; PROTEIN BCL 2; PROTEIN P53; ROSIGLITAZONE; SURVIVIN; TROGLITAZONE; UBIQUITIN; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INVASION; CELL CYCLE ARREST; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; THIAZOLIDINEDIONES;

EID: 78651335893     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0310-9     Document Type: Review

References (53)

1. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med. 1999;16:179-192.
2. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276:37731-37734.
3. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest. 2000;106:467-472.
4. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesityrelated changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007;92:386-395.
5. Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;9:1-9.
6. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004;5:419-429.
7. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol. 2007;25:1476-1481.
8. kip1 in human pancreatic carcinoma cells. Cancer Res. 2000;60:5558-64.
9. Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N, Kohgo Y. Troglitazone induces G1 arrest by p27Kip1 induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res. 2002;93:774-782.
10. Motomura W, Takahashi N, Nagamine M, Sawamukai M, Tanno S, Kohgo Y, et al. Growth arrest by troglitazone is mediated by p27Kip1 accumulation which is resulted from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer. 2004;108:41-46.
11. Koga H, Sakisaka S, Harada M, Hirai A, Miyamoto C, Hatakeyama S, et al. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology. 2001;33:1087-1097.
12. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682-685.
13. Shirane M, Harumiya Y, Ishida N, Hirai A, Miyamoto C, Hatakeyama S, et al. Down-regulation of p27Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolytic processing. J Biol Chem. 1999;274:13886-13893. (Pubitemid 129518688)
14. Carrano AC, Eytan E, Hershko A, Pagano M. Skp2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193-199.
15. Koga H, Harada M, Ohtsubo M, Shishido S, Kumemura H, Hanada S, et al. Troglitazone induces p27Kip1-associated cell cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology. 2003;37:1086-1096.
16. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153-166.
17. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, et al. Inhibition of cellular proliferation through IkappaB kinaseindependent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol. 2001;21:3057-3070.
18. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun. 2001;286:916-922.
19. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F. German and Austrian Adrenal Network. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab. 2005;90:3886-3896.
20. He G, Thuillier P, Fischer SM. Troglitazone inhibits cyclin D1 expression and cell cycling independently ofPPARgammain normal mouse skin keratinocytes. J Invest Dermatol. 2004;123:1110-1119.
21. Motomura W, Tanno S, Takahashi N, Nagamine M, Fukuda M, Kohgo Y, et al. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem Biophys Res Commun. 2005;332:89-94.
22. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, et al. Expression of peroxisome proliferator-activated receptor (PPAR)c in gastric cancer and inhibitory effects of PPARc agonists. Br J Cancer. 2000;83:1394-1400.
23. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator activated receptor gamma in non-small cell lung cancer. Cancer Res. 2000;60:1129-1138.
24. Tsubouchi Y, Sano H, Kawahito Y, Inoue K, Hla T, Sano H. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400-405.
25. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARg inhibits cell growth and induces apoptosis in human gastric cancer cells.FEBSLett. 1999;455:135-139.
26. Nagamine M, Okumura T, Tanno S, Sawamukai M, Motomura W, Takahashi N, et al. PPARr ligand-induced apoptosis through a p53 dependent mechanism in human gastric cancer cell. Cancer Sci. 2003;94:338-343.
27. Wright HM, Clish CB, Mikami T, Hauser S, Yanagi K, Hiramatsu R, et al. A synthetic antagonist for the peroxisome proliferatoractivated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000;275:1873-1877.
28. Shiau CW, Yang CC, Kulp SK, Chen KF, Chen CS, Huang JW, et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005;65:1561-1569.
29. Leung WK, Bai AH, Chan V, Yu J, Chan MW, To KF, et al. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells. Gut. 2004;53:331-338.
30. Mody M, Dharker N, Bloomston M, Wang PS, Chou FS, Glickman TS, et al. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007;14:305-315.
31. Yang FG, Zhang ZW, Xin DQ, Shi CJ, Wu JP, Guo YL, et al. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol Sin. 2005;26:753-761.
32. Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptorgamma- and ERK-dependent in human non-small lung cancer cells. J Cell Physiol. 2006;209:428-438.
33. Srinivasula SM, Ashwell JD. IAPs: what's in a name? Mol Cell. 2008;30:123-135.
34. Oshita F, Ito H, Ikehara M, Ohgane N, Hamanaka N, Nakayama H, et al. Prognostic impact of survivin, cyclin D1, integrin b1, VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol. 2004;27:425-428.
35. Zhou YM, Wen YH, Kang XY, Qian HH, Yang JM, Yin ZF. Troglitazone, a peroxisomeproliferator-activated receptor gamma ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells. World J Gastroenterol. 2008; 14:2168-2173.
36. Schultze K, Böck B, Eckert A, Oevermann L, Ramacher D, Wiestler O, et al. Troglitazone sensitizes tumor cells to TRAILinduced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006;11:1503-1512.
37. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology. 2005;41:237-246.
38. Rachek LI, Yuzefovych LV, Ledoux SP, Julie NL, Wilson GL. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol. 2009;240:348-354.
39. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25:9-34.
40. Durand MK, BØdker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost. 2004; 91:438-449. (Pubitemid 38396865)
41. Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res. 2006;3:159-167.
42. Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, et al. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. Gut. 2004;53:1688-1697.
43. Liu J, Lu H, Huang R, Lin D, Wu X, Lin Q, et al. Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells. Cancer Chemother Pharmacol. 2005;56:400-408.
44. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548-558.
45. Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, et al. Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol. 2006;26:7561-7574.
46. Kumei S, Motomura W, Yoshizaki T, Takakusaki K, Okumura T. Troglitazone increases expression of E-cadherin and claudin-4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009;380:614-619.
47. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 2005;65:9603-9606.
48. Michl P,Barth C, Buchholz B, LerchMM, RolkeM,HolzmannKH, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res. 2003;63:6265-6271.
49. Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgammaindependent signal pathways. Mol Cancer Ther. 2006;5:430-437.
50. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPARgammaindependent antitumor effects of thiazolidinediones. Cancer Lett. 2009;276:119-124.
51. Huang JW, Shiau CW, Yang YT, Kulp SK, Brueggemeier RW, Shapiro CL, et al. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol. 2005;67:1342-1348.
52. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem. 2005;280:6742-6751.
53. Inoue I, Katayama S, Takahashi K, Negishi K, Miyazaki T, Sonoda M, et al. Troglitazone has a scavenging effect on reactive oxygen species. Biochem Biophys Res Commun. 1997;235: 113-116.